nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.12.2011 | Research Paper

Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo

verfasst von: Joseph L. Sottnik, Janet C. Lori, Barbara J. Rose, Douglas H. Thamm

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Metastasis is the primary cause of death from many tumors, and novel anti-metastatic therapies are necessary. Recently, we showed that metastatic tumors down-regulate key oxidative phosphorylation (OXPHOS) genes in favor of glycolysis, a further enhancement of the Warburg effect. Therefore, we sought to determine if restriction of glycolysis using 2-deoxy-d-glucose (2DG) would lead to increased utilization of OXPHOS and inhibition of the metastatic phenotype. Noncytotoxic concentrations of 2DG dose-dependently inhibited in vitro migration and invasion in the highly metastatic DLM8-luc-M1 osteosarcoma (OS) cell line, as well as other metastatic human, canine, and murine cancer cells of different histotypes. This was associated with cytoskeletal rearrangement and inhibition of cathepsin L expression. A dose-dependent shift toward OXPHOS was confirmed by demonstrating increased oxygen utilization and decreased lactate production in 2DG treated cells. Finally, 2DG treatment significantly delayed metastasis and prolonged survival in an orthotopic postsurgical OS model. In conclusion, this work suggests that forcing cells away from glycolysis may inhibit key components of the metastatic phenotype, providing a novel avenue for metastasis prevention.

Nur mit Berechtigung zugänglich

Bielack SS, Carrle D, Hardes J et al (2008) Bone tumors in adolescents and young adults. Curr Treat Option Oncol 9(1):67–80CrossRef

Khanna C (2008) Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep 10(4):350–358PubMedCrossRef

Ramaswamy S, Ross KN, Lander ES et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54PubMedCrossRef

Ptitsyn AA, Weil MM, Thamm DH (2008) Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinform 9(Suppl 9):S8CrossRef

Chen Y, Cairns R, Papandreou I et al (2009) Oxygen consumption can regulate the growth of tumors, a new perspective on the warburg effect. PloS One 4(9):e7033PubMedCrossRef

Ramanathan A, Wang C, Schreiber SL (2005) Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 102(17):5992–5997PubMedCrossRef

Acebo P, Giner D, Calvo P et al (2009) Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol 2(3):138–145PubMed

Amuthan G, Biswas G, Ananadatheerthavarada HK et al (2002) Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 21(51):7839–7849PubMedCrossRef

Amuthan G, Biswas G, Zhang SY et al (2001) Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 20(8):1910–1920PubMedCrossRef

10.

Denhardt DT, Greenberg AH, Egan SE et al (1987) Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 2(1):55–59PubMed

11.

Frade R, Rodrigues-Lima F, Huang S et al (1998) Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 58(13):2733–2736PubMed

12.

Brown J (1962) Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metab Clin Exp 11:1098–1112PubMed

13.

Pelicano H, Martin DS, Xu RH et al (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25(34):4633–4646PubMedCrossRef

14.

Geschwind JF, Ko YH, Torbenson MS et al (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62(14):3909–3913PubMed

15.

Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev 9(6):447–464CrossRef

16.

Sottnik JL, Duval DL, Ehrhart EJ et al (2010) An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis 27(3):151–160PubMedCrossRef

17.

Dehn DL, Siegel D, Zafar KS et al (2006) 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinoneoxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol Cancer Ther 5(7):1702–1709PubMedCrossRef

18.

Janeway KA, Walkley CR (2010) Modeling human osteosarcoma in the mouse: from bedside to bench. Bone 47(5):859–865PubMedCrossRef

19.

Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350(9082):911–917PubMedCrossRef

20.

Liu H, Hu YP, Savaraj N et al (2001) Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542–5547PubMedCrossRef

21.

Maschek G, Savaraj N, Priebe W et al (2004) 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64(1):31–34PubMedCrossRef

22.

Garber K (2004) Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 96(24):1805–1806PubMedCrossRef

23.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

24.

Hua Y, Qiu Y, Zhao A et al (2011) Dynamic metabolic transformation in tumor invasion and metastasis in mice with LM-8 osteosarcoma cell transplantation. J Proteome Res 10(8):3513–3521

25.

Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (New York, NY) 330(6009):1340–1344CrossRef

26.

Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24(50):7435–7442PubMedCrossRef

27.

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324(5930):1029–1033CrossRef

28.

Biswas G, Tang W, Sondheimer N et al (2008) A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling. J Biol Chem 283(18):12586–12594PubMedCrossRef

29.

Guha M, Srinivasan S, Biswas G et al (2007) Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress. J Biol Chem 282(19):14536–14546PubMedCrossRef

30.

Cuezva JM, Krajewska M, de Heredia ML et al (2002) The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62(22):6674–6681PubMed

31.

Willers IM, Isidoro A, Ortega AD et al (2010) Selective inhibition of beta-F1-ATPase mRNA translation in human tumours. Biochem J 426(3):319–326PubMedCrossRef

32.

Simons AL, Fath MA, Mattson DM et al (2007) Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-d-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 69(4):1222–1230PubMedCrossRef

33.

Kurtoglu M, Maher JC, Lampidis TJ (2007) Differential toxic mechanisms of 2-deoxy-d-glucose versus 2-fluorodeoxy-d-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 9(9):1383–1390PubMedCrossRef

34.

Lampidis TJ, Kurtoglu M, Maher JC et al (2006) Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells”. Cancer Chemother Pharmacol 58(6):725–734PubMedCrossRef

35.

Maher JC, Savaraj N, Priebe W et al (2005) Differential sensitivity to 2-deoxy-d-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 30(2):e34–e39PubMedCrossRef

36.

Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ et al (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9(9):1084–1101PubMedCrossRef

37.

Minor RK, Smith DL Jr, Sossong AM et al (2010) Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol 243(3):332–339PubMedCrossRef

38.

Dwarakanath BS, Singh D, Banerji AK et al (2009) Clinical studies for improving radiotherapy with 2-deoxy-d-glucose: present status and future prospects. J Cancer Res Ther 5(Suppl 1):S21–S26PubMedCrossRef

39.

Stein M, Lin H, Jeyamohan C et al (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388–1394PubMedCrossRef

40.

Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6):472–482PubMedCrossRef

41.

Boutros J, Almasan A (2009) Combining 2-deoxy-d-glucose with electron transport chain blockers: a double-edged sword. Cancer Biol Ther 8(13):1237–1238PubMedCrossRef

42.

Fath MA, Diers AR, Aykin-Burns N et al (2009) Mitochondrial electron transport chain blockers enhance 2-deoxy-d-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol Ther 8(13):1228–1236PubMedCrossRef

43.

Ben Sahra I, Laurent K, Giuliano S et al (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70(6):2465–2475PubMedCrossRef

44.

Sahra IB, Tanti JF, Bost F (2010) The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK dependent apoptosis in prostate cancer cells. Autophagy 6(5). doi:10.1158/0008-5472.CAN-09-2782

45.

Zhao Y, Liu H, Liu Z et al (2011) Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71(13):4585–4597PubMedCrossRef

46.

Kurtoglu M, Gao N, Shang J et al (2007) Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 6(11):3049–3058PubMedCrossRef

47.

Maher JC, Wangpaichitr M, Savaraj N et al (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose. Mol Cancer Ther 6(2):732–741PubMedCrossRef

48.

Langbein S, Frederiks WM, Zur Hausen A et al (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122(11):2422–2428PubMedCrossRef

49.

Krockenberger M, Engel JB, Schmidt M et al (2010) Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res 30(5):1653–1659PubMed

50.

Sun W, Liu Y, Glazer CA et al (2010) TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16(3):857–866PubMedCrossRef

51.

Volker HU, Hagemann C, Coy J et al (2008) Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocyticgliomas. Am J Clin Pathol 130(1):50–57PubMedCrossRef

52.

Xu X, Zur Hausen A, Coy JF et al (2009) Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124(6):1330–1337PubMedCrossRef

53.

Xi H, Kurtoglu M, Liu H et al (2011) 2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol 67(4):899–910

Titel: Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo
verfasst von: Joseph L. Sottnik
Janet C. Lori
Barbara J. Rose
Douglas H. Thamm
Publikationsdatum: 01.12.2011
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 8/2011
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9417-5

Springer Medizin

Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2011

High-dose ionizing radiation-induced hematotoxicity and metastasis in mice model

Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer

The effect of down regulation of calcineurin Aα by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis

Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7

Reduction of metastasis using a non-volatile buffer

Highly enriched CD133+CD44+ stem-like cells with CD133+CD44high metastatic subset in HCT116 colon cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie